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49-89% of the total annual costs associated with schizophrenia. ConClusions: 
Schizophrenia imposes a substantial economic burden on society mainly driven by 
high indirect costs. The cost estimates varied due to methodology differences and 
costs included. The information of disease burden associated with schizophrenia 
is crucial to enable informed decision-making in allocating health care resources.
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objeCtives: Due to the rapidly aging population, dementia is becoming a great 
concern in China. Moreover, dementia is associated with an important economic 
burden. The objective of this study was to provide an estimation of the economic 
burden of dementia in China with and without an adequate treatment. Methods: 
A Markov model was developed to simulate transition between a mutually exclusive 
set of health states associated with dementia. Average annual economic burden 
was estimated between patients treated from moderate to severe and patients not 
treated, over a five-year time horizon. The resource categories taken into account 
in the model were treatment, hospitalisations, nursing-home care, biological analy-
ses, imaging, scales and professional caregiver costs. Transition probabilities were 
estimated from clinical trials. The resource utilisation and unit costs were provided 
by a Delphi panel. According to the China Alzheimer’s project, there are 10 million 
dementia patients currently in the country and it is estimated that only 21.3% of 
them take medicine. Results: Over the five year, each untreated dementia patient 
cost on average 40,006 RMB per year, and each treated patient cost 36,503 RMB per 
year. Given current dementia patients of 10 million in China, and a treated prob-
ability of 21.3%, the annual total costs resulted in an economic burden of 392.6 
billion RMB per year for dementia patients in China. Because of the demographic 
evolution of the Chinese population, the number of dementia patients is expected 
to increase. Increasing the proportion of treated patients might be a way to limit 
the raise of the burden, as the treatment help to reduce the average annual health 
care costs. ConClusions: Burden of dementia in China is likely to grow since 
the expanding ageing population. Adequate disease management using available 
treatment may be an efficient solution to limit costs.
PMH12
eConoMIC Burden of deMentIa In sIngaPore: PrelIMInary results
Wang V.W.1, Kandiah N.2, Lin X.2, Wee H.L.1
1National University of Singapore, Singapore, 2National Neuroscience Institute, Singapore
objeCtives: With a rapidly ageing population, dementia has become a major public 
health problem worldwide. Around 28,000 Singaporeans aged 60 and above have 
dementia, and the number is projected to hit 80,000 by 2030, imposing a poten-
tially significant economic burden on individuals and society which has yet to be 
quantified. Therefore we sought to assess the annual economic burden of dementia 
in Singapore and to identify the main cost components. Methods: In this cross-
sectional study approved by the SingHealth Centralised Institutional Review Board, 
consecutive patients seen at the dementia clinic of National Neuroscience Institute 
(NNI) between August 2013 and December 2014 were recruited. Singapore residents 
meeting the National Institute of Neurological Disorders and Stroke criteria for the 
diagnosis of dementia with follow-up of at least 6 months at NNI were included. 
Caregivers of eligible patients were interviewed with a financial burden question-
naire to collect direct and indirect costs related to dementia over the past 12 months 
from a societal perspective. Results: Of 60 patients aged 54-91 years (median: 74) 
recruited, 90% were Chinese, 42% were men, and 38% had Young Onset Dementia 
(YOD) (defined as dementia onset before age 65). Annual total cost of dementia was 
SGD28341 per patient (i.e. $793 million for the country), with direct cost constituting 
23% and indirect cost constituting 77%. The main cost components for direct medical 
cost, direct non-medical cost, and indirect cost were pharmacotherapy (52%), home 
care (45%), and productivity loss (72%), respectively. As expected, the indirect cost 
of YOD patients was significantly higher than non-YOD patients. ConClusions: 
Dementia imposes a considerable economic burden in Singapore. As productivity 
loss accounts for a large share of the burden especially in YOD group, programs to 
improve early diagnosis, raise public awareness about the disease, reduce stigma 
and provide better support to caregivers are urgently needed.
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objeCtives: As reported by Chinese Center for Disease Control and Prevention in 
2009, there have been more than 10 million patients with schizophrenia in China, 
with the incidence of about 7.81‰. This article is to evaluate the economic burden of 
schizophrenia in Chinese city based on societal perspective and to detect its impact 
factors. Methods: 2010-2012 databases of Urban Employee Basic Medical Insurance 
and Urban Residents Basic Medical Insurance, as well as disability adjusted life year 
(DALY), were used to estimate direct cost and indirect cost caused by schizophrenia 
in Guangzhou, which is a large city in China with a population of over 8.5 million and 
the per capita GDP of approximately US$16,000. Results: During 2010-2012, direct 
costs of schizophrenia in Guangzhou city were RMB 95.69 million, 168.62 million, 
and 197.70 million (US$ 14.72 million, 25.94 million, and 30.42 million); indirect costs 
of schizophrenia were RMB 1,096.68 million, 1,201.89 million, and 1,375.08 million 
(US$ 168.72 million, 184.91 million, and 211.55 million). The ratio of direct economic 
loss to indirect economic loss was 1 to 8.5. Direct cost and indirect cost caused by 
schizophrenia in Guangzhou city were increasing in recent years. Medical costs 
of inpatients and people with Urban Employee Basic Medical Insurance mainly 
objeCtives: PERFORM-K (ePidEmiological Research on Functioning Outcomes 
Related to Major depressive disorder (MDD) in South-Korea) is a cross-sectional 
observational study conducted in South-Korea, with similar selection criteria and 
assessment to the PERFORM study in Europe. The main objective of the study is 
to describe the functioning of patients with MDD, the impact of cognitive dys-
function and the factors associated with functional impairment. Methods: 343 
outpatients were recruited by psychiatrists. Inclusion criteria were: DSM-IV-TR diag-
nosis of MDD, 19 to 65 years antidepressant monotherapy (initiation or first switch). 
Depression severity was evaluated with MADRS (Montgomery–Åsberg Depression 
Rating Scale) by psychiatrists and PHQ-9 (Patient Health Questionnaire 9-item) 
by patients. Functioning was measured by SDS (Sheehan Disability Scale), work 
productivity by WPAI (Work Productivity and Activity Impairment Questionnaire) 
and cognitive dysfunction by PDQ-D (Perceived Deficit Questionnaire-Depression). 
Descriptive analyses from functioning and activity questionnaires were comple-
mented with multivariate ANCOVA. Results: The 312 analyzable patients had a 
mean age of 45.2 years. 74.0% were women, 41.7% were employed and 22.8% had 
their treatment switched when visiting their psychiatrists. Mean MADRS and PHQ-9 
scores were respectively 28.9 and 16.0 respectively. Overall functioning was impaired 
(mean SDS= 16.7), as was overall activity (57.9% impairment on WPAI-4); 25.1% of the 
patients reported a PDQ-D score ≥ 44. In multivariate analyses, overall functional 
impairment (SDS) was associated with greater depression severity (p= 0.022), greater 
patient-reported cognitive dysfunction (p< 0.001), presence of sick leave in previous 
12-months (p= 0.004), younger age (p= 0.011) and region (p = 0.004). Overall activity 
impairment (WPAI-4) was associated with greater depressive severity (p= 0.043), 
greater cognitive dysfunction (p< 0.001) and younger age (p= 0.001). ConClusions: 
Functional impairment in MDD is not only associated with the severity of depres-
sion, but also with cognitive function, previous sick leave, age and region. This is 
consistent with findings from PERFORM in Europe.
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objeCtives: To review literatures that reported prevalence/incidence related to 
Major Depressive Disorder (MDD) in China. Methods: A structured literature 
review on published articles in both English and Mandarin language was con-
ducted. Search engines used for literature review were PUBMED, Cochrane Library, 
Wan Fang and VIP database.The review included primary studies or meta-analyses 
of prevalence or incidence studies of MDD published between 2000 and 2013 on 
Chinese population based in China only (including Hong-Kong and Macau). Four 
reviewers (two for each language) reviewed and extracted all relevant information 
from the selected articles. Results: One meta-analysis and 7 studies not included 
in the meta-analysis were identified. In the meta-analysis, the nationwide point 
prevalence of MDD was estimated to be 1.6% (95% CI: 1.2-1.9), 12-month prevalence 
to be 2.3% (95% CI: 1.8-5.5) and lifetime prevalence to be 3.3% (95% CI: 2.4-4.1). 
Point prevalence was higher in rural compared to urban areas. The other studies 
conducted across different regions reported point prevalence ranging from 3.6% 
to 9.4%, 12-month prevalence from 3.8% to 8.4% and lifetime prevalence of 6.5% to 
10%. A hospital-based study reported higher estimates (point prevalence of 7.5% 
and lifetime prevalence of 10%), possibly reflective of higher prevalence of MDD in 
patients with physical comorbidity or patients seeking help at hospitals. 11.0% to 
16.3% of patients with MDD were reported to have attempted suicide within 1 year, 
more frequently among patients from rural compared to urban area. About 27-28% 
of patient who committed suicide had history of MDD. ConClusions: The preva-
lence of MDD in China reported was variable between regions. The possible reason 
for this difference could be due to geographical and methodological differences. 
However, the reported prevalence was lower compared to that in western countries. 
Overall, the burden of MDD in China remains high due to its large population size.
Mental HealtH – Cost studies
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objeCtives: Schizophrenia is one of the most devastating mental illnesses. Despite 
low prevalence, health and economic consequences related to schizophrenia have 
been significant. Economic burden studies have been used to measure the mag-
nitude of the burden of this under-diagnosed and under-treated disabling condi-
tion to the society. To understand how previous studies on estimating economic 
burden of schizophrenia have been conducted, the present systematic review 
focuses on the methodology undertaken by these studies. Methods: Pubmed, 
EMBASE and PsycINFO were searched for publications from inception to October 
2013. Inclusion criteria were: (i) article measuring cost of schizophrenia; (ii) article 
reporting economic burden; (iii) information on the primary cost data was avail-
able; and (iv) article in English. Data from all eligible articles were extracted using 
a standardised data collection form. Costs were converted to 2013 USD. Results: 
Forty studies were included covering 24 countries – 12 countries (50%) in Europe. 
Almost half of the studies (55%) were conducted at selected institutions while 35% 
at the national level. Prevalence-based approach was adopted in 95% studies, while 
only 5% used incidence-based estimation. Costs were determined using bottom-
up (45%), top-down (33%) or combination of both (23%). Electronic databases (68%) 
and patient/family/health care provider (60%) were the main data sources used. 
The total annual direct medical costs reported in the national studies varied from 
USD 30 to 29,316 million and direct non-medical costs from USD 32 to 12,029 mil-
lion. Indirect costs ranged from USD 63 to 41,767 million per year, contributing to 
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objeCtives: The aim of our study is to calculate the annual health insurance 
treatment cost of anxiety in Hungary. Methods: The data derive from the finan-
cial database of the Hungarian National Health Insurance Fund Administration 
(NHIFA), the only health care financing agency in Hungary. We analyzed the 
health insurance treatment cost and the number of patients for the year 2010. 
The following cost categories were included into the study: out-patient care, in-
patient care, CT-MRI, PET, home care, transportation, general practitioner, drugs 
and medical devices. Results: The Hungarian National Health Insurance Fund 
Administration spent 13.535 billion Hungarian Forint (HUF) (65.026 million USD) 
for the treatment of anxiety patients. The annual average expenditure per patient 
was 13323 HUF (64 USD) while the average expenditure per one inhabitant was 1352 
HUF (6.5 USD). Major cost drivers were general practitioners of primary care (43.8 
% of total health insurance costs), pharmaceuticals (32.2 %) and outpatient care 
(12.4 %). The number of patients with anxiety disease was 1014 per 100000 popula-
tions. We found the highest patient number in general practitioners of primary care 
(1015938 patients), pharmaceuticals (774096 patients) and outpatient care (521760 
patients). ConClusions: Anxiety represents a significant burden for the health 
insurance system. General practitioners of primary care and pharmaceutical reim-
bursement are the major cost drivers for anxiety disease in Hungary.
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objeCtives: Resulting from the scarcity of literature on dementia in China, a 
Delphi panel was used to obtain information on disease management, resource 
utilisation and associated costs for patients with moderate or severe dementia in 
China. The panel results were used as input data for a health economic model com-
paring different alternative strategies for treatment of dementia. Methods: The 
Delphi panel method was used to leverage expertise of physicians involved in the 
treatment of dementia (Round-1 interviews with eight interviewees) and hospital 
administrators (Round-2 interviews with two interviewees). Final Delphi meeting 
gathered six experts from previous interviewees to reach a consensus. Round-1 
interviews collected information of establishing a diagnosis for dementia, dementia 
disease management and the distribution of patients by severity, dependence and 
aggressiveness. Round-2 interviews were based on results of Round-1 interviews 
to collect data on relevant costs. Interviews were done individually without shar-
ing information from other interviewees. Results from two rounds were integrated 
and shared in the final Delphi discussion. A consensus was reached to obtain the 
final value or range of values of interest. Results: Distribution of independent/
non-aggressive, independent/aggressive, dependent/non-aggressive, and depend-
ent/aggressive moderate dementia patients was 70%, 15%, 10% and 5% at time 
of first diagnosis . Unit costs and resources utilisation, collected for each health 
state for a cycle of 6-months, showed that severe dependent/aggressive dementia 
patients required the most time from caregivers (15 hours/day). Moderate depend-
ent/aggressive patients had the highest probability (90%) to be hospitalised. The 
average stay of hospitalisation was two months. Moderate and severe patients had 
the same probability of nursing home utilisation (0%, 20%, 80% and 20% for each 
health state). ConClusions: Delphi panel may be a useful approach to collect 
data for diseases when they are not published in the literature or when automated 
health care databases are not available or accessible.
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objeCtives: To review studies that investigated the costs and resource use of 
managing major depressive disorder (MDD) in China. Methods: A structured 
literature review on published articles in both English and Mandarin languages 
was conducted. Literature search was conducted using PubMed, Cochrane, Wan 
Fang, and VIP databases. Articles published between 2000 to 2013 were selected. The 
inclusion criteria included studies conducted in China, and studies that reported 
direct and indirect costs in MDD management, including factors that affected these 
costs, as well as resources used in managing MDD. Four reviewers (two for each 
language) independently selected and reviewed the articles. Direct cost included 
costs of MDD treatment (e.g. medication, investigation, hospitalisation, nursing 
care…etc.); whereas indirect costs included caregiver cost, productivity loss, and 
mortality (suicide). Results: A total of 24 articles in Mandarin and English were 
selected and reviewed. Based on the review, direct cost for MDD reported ranged 
from RMB 1,000 to RMB 6,000, whereas indirect cost reported ranged from RMB 
2,000 to RMB 51,000. Loss of productivity, when evaluated, accounted for more than 
75% of indirect costs. Serotonin norepinephrine reuptake inhibitor (SNRI) incurred 
the highest direct medical cost compared to selective serotonin reuptake inhibitor 
(SSRI), followed by tricyclic antidepressants (TCA). The treatment costs for MDD 
had increased gradually over the years. Some of the common factors affecting the 
cost of MDD management included treatment duration, payment methods, types 
of drug prescribed, comorbidity, disease severity and marital status. Studies had 
shown that most patients first seek treatment in general clinic or hospitals (76%) 
consisted of the direct economic burden of this disease. ConClusions: Serious 
economic burden has been caused by schizophrenia and increased sharply in China. 
Indirect cost of schizophrenia is largely more than its direct cost.
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objeCtives: Ziprasidone is increasingly used for the treatment of schizophrenia 
and bipolar disorder. The purpose of this study is to compare health care costs 
and utilization associated with use of ziprasidone and olanzapine. Methods: 
Schizophrenia and bipolar disorder patients who initiated use of ziprasidone or 
olanzapine between 01/2007 and 12/2010 were identified in the IMS LifeLink™ 
Health Plan Claims Database. Claims were summarized into treatment episodes, 
and one-year costs and utilization after the initiation of episodes were analyzed. 
OLS regressions, general liner models, and two-part models were used to com-
pare various types of costs associated with the use of ziprasidone and olanzapine. 
Logistic regressions, Poisson regressions, and Hurdle models were used to com-
pare the numbers of emergency room visits and hospitalizations associated with 
each drug. Lastly, we used various statistical methods to test the sensitivity of our 
estimates. Results: We identified 7,138 (46.93%) ziprasidone episodes and 8,072 
(53.07%) olanzapine episodes, and found that patients using ziprasidone were signif-
icantly younger (41.50 vs. 45.38) and were significantly less likely to be male (29.81% 
vs. 44.21%). At baseline, ziprasidone group and olanzapine group differed in total 
costs and several other components of costs. Benchmark analyses show that use of 
ziprasidone, when compared to olanzapine, was associated with significantly higher 
medication costs ($232, p< 0.01) and outpatient costs ($501, p< 0.05), but decreased 
ER costs (-$73, p< 0.05). Ziprasidone was also associated with significantly fewer 
ER visits (0.266, p< 0.001) and hospitalizations (1.117, p< 0.001). Sensitivity analyses 
suggest these results were robust. ConClusions: While ziprasidone is associated 
with higher medication costs and outpatient costs, it reduces patients’ utilization 
of ER and inpatient services.
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objeCtives: The aim of our study is to calculate the annual health insurance 
treatment cost of Alzheimer dementia disease in Hungary. Methods: The data 
derive from the financial database of the Hungarian National Health Insurance 
Fund Administration (NHIFA), the only health care financing agency in Hungary. We 
analyzed the health insurance treatment cost and the number of patients for the 
year 2010. The following cost categories were included into the study: out-patient 
care, in-patient care, CT-MRI, PET, home care, transportation, general practitioner, 
drugs and medical devices. Results: The Hungarian National Health Insurance 
Fund Administration spent 4.426 billion Hungarian Forint (HUF) (21.266 million 
USD) for the treatment of Alzheimer patients. The annual average expenditure per 
patient was 72881 HUF (350 USD) while the average expenditure per one inhab-
itant was 442 HUF (2.1 USD). Major cost drivers were acute inpatient care (45.8 
% of total health insurance costs), chronic inpatient care (28.1 %) and pharma-
ceuticals (10.4 %). The number of patients with Alzheimer disease was 60.6 per 
100000 populations. We found the highest patient number in outpatient care budget 
(60735 patients), general practitioners (60234 patients) and pharmaceuticals (37724 
patients). ConClusions: Alzheimer dementia disease represents a significant bur-
den for the health insurance system. Hospital care (both acute and chronic) is the 
major cost driver for Alzheimer disease in Hungary.
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objeCtives: To study the treatment pattern and cost of illness in bipolar disorder 
patients in tertiary care hospital in South India. Methods: A retrospective study 
was conducted in a tertiary care teaching hospital of South India. Data were col-
lected retrospectively from medical record section from 2012 to 2013 in suitable 
designed case record form. Data were analysed by using SPSS 20.0. Results: Total 
of 100 cases of bipolar disorder was followed during the study period. Among them 
66 were males and 34 were females. The mean age of the study population was 
found to be 46.2+13.3 years. Among the social history 13 people were alcoholic and 
60% of the study population had a family history of known psychiatric disorder. 
The mean duration of illness of the study population was found to be21.8+9.8years. 
Among the study population 34 patients were diagnosed with mania and 46 patients 
diagnosed with depression. Mood examination revealed that 38 patients were happy 
followed by 22 patients were irritable. Affective examinations showed maximum 
were euphoric. Insight examination showed Grade 1 predominance. The different 
treatment pattern revealed that all of them were prescribed with mood stabilizer 
followed by anti-psychotic (93) and hypnotics (86). The average hospitalization cost 
of the patient was found to be 7477.83 + 5989.67 Rupees with median hospital stay 
of 7(5) days. The average treatment cost constitutes total 50% of the hospitalization 
cost. ConClusions: Mood stabilizers and anti-psychotics were the main treatment 
strategies among the bipolar patients and drug cost consumes 50% of the total cost 
of hospitalization. Pharmacoeconomic studies plays important role in estimating 
the total health care burden in bipolar disorders.
